We describe procedures for repeated administration of inhibitors of muscarinic signaling to the levator auris longus (LAL) muscle of young adult mice and for subsequent immunostaining of its neuromuscular junctions (NMJs) in wholemounts. The LAL muscle has unique advantages for revealing in vivo pharmacological effects on NMJs.
Hind limb muscles of rodents, such as gastrocnemius and tibialis anterior, are frequently used for in vivo pharmacological studies of the signals essential for the formation and maintenance of mammalian NMJs. However, drug penetration into these muscles after subcutaneous or intramuscular administration is often incomplete or uneven and many NMJs can remain unaffected. Although systemic administration with devices such as mini-pumps can improve the spatiotemporal effects, the invasive nature of this approach can cause confounding inflammatory responses and/or direct muscle damage. Moreover, complete analysis of the NMJs in a hind limb muscle is challenging because it requires time-consuming serial sectioning and extensive immunostaining.
The mouse LAL is a thin, flat sheet of muscle located superficially on the dorsum of the neck. It is a fast-twitch muscle that functions to move the pinna. It contains rostral and caudal portions that originate from the midline of the cranium and extend laterally to the cartilaginous portion of each pinna. The muscle is supplied by a branch of the facial nerve that projects caudally as it exits the stylomastoid foramen. We and others have found LAL to be a convenient preparation that offers advantages for the investigation of both short and long-term in vivo effects of drugs on NMJs and muscles. First, its superficial location facilitates multiple local applications of drugs under light anesthesia. Second, its thinness (2-3 layers of muscle fibers) permits visualization and analysis of almost all the NMJs within the muscle. Third, the ease of dissecting it with its nerve intact together with the pattern of its innervation permits supplementary electrophysiological analysis in vitro9,5. Last, and perhaps most importantly, a small applied volume (˜50μl) easily covers the entire muscle surface, provides a uniform and prolonged exposure of all its NMJs to the drug and eliminates the need for a systemic approach1,8.
1. Subcutaneous administration of muscarinic acetylcholine receptor (mAChR) antagonists
2. Dissection of LAL muscles
3. Triple immunostaining of LAL NMJs: Day 1
4. Triple immunostaining of LAL NMJs: Day 2
5. Confocal imaging of LAL NMJs
Representative results:
At the adult mammalian NMJ, a single motor axon elaborates fine branches that form highly differentiated arbors of a nerve terminal (Fig. 2; Green) on a single muscle fiber, precisely apposed to postsynaptic clusters of nicotinic AChRs (Fig. 2; Red). Perisynaptically, terminal Schwann cells tightly cover all the branches of presynaptic nerve terminals (Fig. 2; Blue). The structural and functional integrity of this tripartite organization is severely perturbed by daily application of subtype-specific mAChR inhibitors. In the example presented here (Fig. 3), 4-DAMP, a mAChR antagonist with high affinity for M1, M3, M4 and M5 mAChR subtypes , evokes selective elimination of nerve terminals from numerous NMJs throughout the muscle surface (Fig. 3B, C). In addition, terminal Schwann cells are abnormally quiescent8 as evidenced by bright S100 labeling without process extension (Fig. 3B”, 3C”). Postsynaptically, muscle fibers are normal and there is no loss of nAChRs (Fig. 3B’, 3C’).
Figure 1. Anatomical location and organization of the LAL muscle. Location of rostral (rLAL), caudal (cLAL), and the LAL nerve (LALn) and corresponding endplate bands are shown (A, inset). The location and orientation of the needle in respect to the LAL muscle is shown for the injection procedure (B). Incision points are shown for the dissection procedure (C).
Figure 2. Tripartite organization of the NMJ. High-magnification confocal views of a mouse NMJ. A single axon elaborates fine terminal branches (A), tightly covered by terminal Schwann cell and their processes (A’, asterisks point to terminal Schwann cell bodies). Postsynaptically in a muscle fiber, a cluster of nicotinic AChRs is precisely apposed to the branches of nerve terminals and terminal Schwann cells.
Figure 3. LAL muscles treated with 4-DAMP, a mAChR antagonist. Low and high-magnification confocal views of LAL muscles treated with vehicle or 4-DAMP. In contrast to the vehicle-treated muscle (A-A”’), numerous NMJs in the 4-DAMP-treated muscle lack nerve terminals (B-B”’, C-C”’). A boxed area in Figure 2B is zoomed in Figure 2C.
The method presented here permits investigation of previously unrecognized roles of subtype-specific mAChR signaling in the stability and maintenance of mammalian NMJs. This method will also be useful to test the effects of neurotrophic factors and pharmacological agents. For example, our laboratory found that Ciliary Neurotrophic Factor (CNTF) elicited sprouting from nearly all LAL nerve terminals in adult mice1. This result contrasted with prior studies of CNTF-treated hind limb muscles, which reported moderate sprouting at ca. 13-33% of gluteus and at 9% of lateral gastrocnemius junctions3. We believe the discrepancy was due to more uniform and prolonged exposure of nerve terminals to CNTF in LAL than in hind limb muscles. Indeed, when we applied CNTF to lateral gastrocnemius and tibialis anterior muscles using the same protocol that elicited widespread sprouting from nearly all LAL NMJs, we observed weak sprouting from only a modest number of NMJs that was preferentially located near the injection sites. Apparently, exposure of the hindlimb NMJs to CNTF had been limited and uneven, as also noted in a previous study2. On the other hand, CNTF injected between the subdermal connective tissue and the LAL fascia, but not CNTF injected subcutaneously into hind limb muscles, formed a local, subdermal swelling that persisted for at least one hour before vascular reabsorption. It is also notable that even when the injection frequency of CNFT or mAChR antagonists was increased to up to four times daily, we did not observe particularly additive effects of CNTF and mAChR antagonists. In addition, if the injection procedure is performed appropriately, it is unlikely that any direct muscle damage would occur. However, if one did damage the muscle during the injection procedure, axonal sprouting at the nerve terminal or at the nodes, and/or muscle fiber degeneration could be observed1,8. In summary, LAL muscles are a unique preparation that permits uniform, prolonged exposure of all NMJs within a muscle with relatively easy and quick procedures.
The narrower caudal portion of a LAL muscle is thicker (3-5 muscle fibers thick) than the wider rostral portion (2-3 muscle fiber thick). Accordingly, NMJs associated with muscle fibers deeply positioned in caudal LAL are often either not labeled in wholemount immunostaining or labeled only by α-bungarotoxin, which penetrates more deeply than antibodies due to its smaller size and high affinity for nAChRs. These NMJs can be misinterpreted as having lost nerve terminals or Schwann cells due to specific effects of the applied drugs. It is therefore important to note whether these junctions are only observed in caudal LAL, and whether the NMJs or muscle fibers are superficially or deeply positioned: superficially positioned muscle fibers are usually associated with much higher background immunofluorescence than deeply positioned fibers. Alternatively, one can omit deeply positioned NMJs in the caudal strip of the LAL from wholemount analysis.
Although complete transection of LAL nerves is relatively easy and permitted us to study the effects of mAChR inhibition on denervated muscles, the size and accessibility of the LAL nerves limit the types of surgical approaches that can be investigated. For example, partially damaging LAL nerve in order to induce partial denervation of a LAL muscle seems technically quite challenging.
The authors have nothing to disclose.
This work was supported by Muscular Dystrophy Association, NIH (NS062320).
Name of the reagent | Company | Catalogue number | Yorumlar |
---|---|---|---|
ketamine | Hospira | NDC0409-2051-05 | Dose: 120mg/kg |
xylazine | Lloyd Laboratories | LA33806 | Dose: 8mg/kg |
atropine | Sigma-Aldrich | A0132 | (>98% purity); Dose: 0.2mg/kg – 20mg/kg |
atropine | Voigt Global Distribution | AT105 | Pharmaceutical grade |
Methoctramine | Sigma-Aldrich | M105 | Dose: 100 – 400M |
4-DAMP | Sigma-Aldrich | D142 | Dose: 2.5mg/kg |
AFDX-116 | Tocris Bioscience | 1105 | 250M |
AFDX-384 | Tocris Bioscience | 1345 | 50M – 500M |
MT 7 | Peptides International | PMT-4340-s | 0.1M – 1M |
1X Phosphate Buffered Saline, pH 7.4 | Invitrogen | 10010049 | |
Paraformaldehyde | Fisher | T353-500 | Make 10% solution first by dissolving 10g/100mL de-ionized distilled water; make 4% with 1X PBS, adjust pH to 7.4 |
Sodium pentobarbitol | Virbac Animal Health | NDC-051311-050-01 | Dose: 390mg/kg |
Sylgard | Dow Corning | Part # 184 | Follow instructions that come with kit, can use multiple sized culture dish (30mm, 60mm, 100mm) depending on needs |
0.1M Glycine | Sigma-Aldrich | G-7126 | Add 0.185g to 25mL of 2% BSA/PBS |
2% Bovine serum albumin (2% BSA) | Sigma-Aldrich | A3059-100g | Dissolve 2g BSA into 100mL of 1X PBS |
0.2% Triton X100 in 2% BSA/PBS (Blocking Buffer) | Sigma-Aldrich | T9284-100mL | Dissolve 0.2ml/100mL 2% BSA/PBS |
α-bungarotoxin | Invitrogen | T1175 | Use at concentration of 1:200 |
SMI-312 | Sternberger Monoclonals | SMI312 | Use at concentration of 1:1000 |
SV2 | Developmental Studies Hybridoma Bank | SV2-Supernatant | Use at concentration of 1:10 |
S100 | Dako | Z0311 | Use at concentration of 1:400 |
FITC- goat anti-mouse IgG1 | Roche | 03117731001 | Use at concentration of 1:200, but if background is high, try 1:400 |
Alexa-Fluor 647 conjugated goat anti-rabbit | Invitrogen | A21244 | Use at concentration of 1:200 |
Vectashield fluorescent mounting media | Vector laboratories | H-1000 | This is not a hard-set media, you will need to secure the cover slip with clear nail polish. |
Small Spring Scissors | Fine Science Tools | 15002-08 | |
Dissection forceps | Fine Science Tools | 11295-51 |